

Title: Efficacy of Tirzepatide Dual GIP/GLP-1 Receptor Agonist In Patients with Idiopathic Intracranial Hypertension. A Real-World Propensity Score-Matched Study.

Ahmed Y. Azzam^{1,2}, Muhammed Amir Essibayi^{1,2}, Nathan Farkas³, Mohammed A. Azab⁴, Mahmoud M. Morsy⁵, Osman Elamin⁶, Adam Elswedy⁷, Ahmed Saad Al Zomia⁸, Hammam A. Alotaibi⁹, Ahmed Alamoud⁸, Oday Atallah¹⁰, Hana J. Abukhadijah^{11*}, Adam A. Dmytriw^{12, 13}, Amanda Baker^{1,2}, Deepak Khatri², Neil Haranhalli², David J. Altschul^{1,2}

- 1- Montefiore-Einstein Cerebrovascular Research Lab, Albert Einstein College of Medicine, Bronx, NY, USA.
- 2- Department of Neurological Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
- 3- Department of Radiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
- 4- Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland, OH, USA.
- 5- October 6 University Hospital, October 6 University, 6th of October City, Giza, Egypt.
- 6- Department of Neurosurgery, Jordan Hospital, Amman, Jordan.
- 7- Biomedicinskt Centrum BMC, Uppsala University, Husargatan 3, 752 37 Uppsala, Sweden.
- 8- College of Medicine, King Khalid University, Abha, Saudi Arabia.
- 9- Ophthalmology Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
- 10- Department of Neurosurgery, Hannover Medical School, Hannover, Germany.
- 11- Medical Research Center, Hamad Medical Corporation, Doha, Qatar.
- 12- Neuroendovascular Program, Massachusetts General Hospital & Brigham and Women's Hospital, Harvard University, Boston, MA, USA.
- 13- Neurovascular Centre, Divisions of Therapeutic Neuroradiology & Neurosurgery, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.

Corresponding Author*:

Hana J. Abukhadijah,

Medical Research Center,

Hamad Medical Corporation,

Doha Qatar, P.O. Box 3050,

Email Address: HAbukhadijah@hamad.qa

Abstract:

Introduction: Idiopathic intracranial hypertension (IIH) is a neurological disorder characterized by elevated intracranial pressure, predominantly affecting obese women of reproductive age. While GLP-1 receptor agonists have shown promise in IIH management, the potential of dual GIP/GLP-1 receptor activation through tirzepatide remains unexplored. This study aimed to evaluate tirzepatide's efficacy as an adjunctive therapy in IIH management.

Methods: We conducted a retrospective cohort analysis using the TriNetX Global Health Research Network, analyzing data through November 2024. Through propensity score matching, we compared 193 tirzepatide-exposed IIH patients with 193 controls receiving standard care. Primary outcomes included papilledema severity, visual function, headache frequency, and treatment resistance, monitored at multiple follow-up timepoints.

Results: Our analysis revealed significant improvements across all measured outcomes in the tirzepatide group. At 24 months, we observed a 68% reduction in papilledema risk (RR 0.320, 95% CI 0.189-0.542, $p < 0.001$), a 73.9% reduction in visual disturbance and blindness risk (RR 0.261, 95% CI 0.143-0.477, $p < 0.001$), and a 19.7% reduction in headache risk (RR 0.803, 95% CI 0.668-0.966, $p = 0.019$). The tirzepatide group demonstrated significant body-mass index reductions, reaching -1.147 kg/m^2 (95% CI $[-1.415, -0.879]$, $p < 0.001$) at 24 months compared to controls.

Conclusions: Our results demonstrate that tirzepatide, when used as an adjunctive therapy, provides significant therapeutic benefits in IIH management, particularly in improving papilledema and visual outcomes. Our findings suggest that dual GIP/GLP-1 receptor activation may offer advantages over traditional single-receptor therapies, potentially through enhanced metabolic regulation and direct effects on intracranial pressure dynamics.

Keywords: Idiopathic Intracranial Hypertension; Pseudotumor Cerebri; Tirzepatide; Papilledema; Headache

1. Introduction:

Idiopathic intracranial hypertension (IIH) is a neurological disorder characterized by elevated intracranial pressure (ICP) without an identifiable underlying cause [1, 2]. The condition predominantly affects women of reproductive age with obesity, manifesting through debilitating symptoms including chronic headaches and papilledema, which can lead to permanent visual impairment if left untreated [1, 3]. The pathophysiology of IIH is complex and multifactorial, involving obesity-related mechanisms such as increased intra-abdominal pressure affecting cerebral venous drainage and adipose tissue functioning as an endocrine organ, releasing factors that influence ICP and neuroinflammation [3-5]. Current standard management approaches include medical therapies such as acetazolamide, which reduces cerebrospinal fluid (CSF) production, topiramate, which combines ICP-lowering and migraine prophylaxis effects, and other diuretics [2, 3]. In cases refractory to medical management, surgical interventions including venous sinus stenting, optic nerve sheath fenestration (ONSF), and CSF shunting procedures may be necessary [3, 4, 6].

However, current management options face significant limitations [5, 7]. Medical therapies often produce suboptimal responses, with many patients experiencing persistent symptoms or intolerable side effects that lead to poor compliance [2, 8]. Surgical interventions, while effective in selected cases, carry inherent risks and may require revision procedures [3, 4]. Furthermore, while weight loss has demonstrated effectiveness in IIH management, achieving and maintaining significant weight reduction through lifestyle modifications alone proves challenging for many patients [7], highlighting the need for more effective therapeutic approaches.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a promising therapeutic option for IIH [1, 5]. Originally developed for type 2 diabetes management, these agents work by enhancing insulin release, suppressing glucagon, and slowing gastric emptying [1, 5]. Recent evidence has revealed that GLP-1 receptors are present in the brain, including the hypothalamus and choroid plexus, suggesting potential direct effects on CSF production and ICP regulation [1-3]. Clinical studies have demonstrated encouraging results regarding the safety and efficacy of GLP-1 RAs in IIH management [2, 8]. For instance, clinical trials with exenatide showed significant ICP reductions of 5.7 cm CSF within hours of administration, with sustained effects at 12 weeks [2]. Additionally, studies have reported substantial improvements in headache frequency and severity, with 76.9% of patients achieving at least a 50% reduction in monthly headache days when treated with GLP-1 RAs like semaglutide or liraglutide [5, 8].

While current evidence supporting GLP-1 RAs in IIH treatment is promising, studies have primarily focused on exenatide, a short-acting GLP-1 RA [2, 5]. Notably absent from the literature is investigation into tirzepatide's efficacy in IIH management. Tirzepatide represents a unique dual GIP/GLP-1 receptor agonist with potentially superior weight loss effects and metabolic benefits compared to single-receptor GLP-1 RAs [5]. Given its dual receptor activity

and enhanced weight reduction potential, tirzepatide may offer additional benefits for IIH patients through both direct ICP-lowering effects and sustained weight management [4, 5, 8].

This international multicenter study aims to evaluate the efficacy of tirzepatide as an adjunctive therapy to standard IIH management using the TriNetX database [1, 2]. Our retrospective cohort analysis represents the first large-scale investigation of tirzepatide's role in IIH treatment. The study's strengths include its substantial sample size, diverse international patient population, and real-world clinical setting, which enhance the generalizability of our findings. By analyzing tirzepatide's effectiveness as an adjunctive therapy rather than monotherapy, our study design reflects practical clinical scenarios and provides valuable insights into optimizing IIH management strategies [5, 8].

2. Methods:

2.1. Patient Selection and Cohort Establishment:

We utilized the TriNetX Global Health Research Network (TriNetX, Cambridge, MA, USA), a federated real-time platform integrating electronic health records from approximately 160 healthcare organizations worldwide [9]. TriNetX network (<https://trinetx.com/solutions/live-platform/>) encompasses around 197 million patient records across multiple countries, including the United States as the predominant source, along with healthcare data from Australia, Belgium, Brazil, Bulgaria, Estonia, France, Georgia, Germany, Ghana, Israel, Italy, Japan, Lithuania, Malaysia, Poland, Singapore, Spain, Taiwan, United Arab Emirates, and the United Kingdom. Our study leveraged data through November 2024, representing the complete available timeframe in the dataset. The TriNetX platform provides comprehensive patient-level information including demographics, diagnoses, treatments, procedures, and clinical outcomes, coded using standardized medical classification systems such as the International Classification of Diseases, Tenth Revision (ICD-10) and Current Procedural Terminology (CPT) codes. All data within the network are automatically standardized and harmonized to enable consistent analysis across different healthcare organizations and geographical regions. The platform ensures HIPAA compliance through automatic de-identification of patient data while maintaining the integrity of longitudinal records for research purposes.

We utilized the electronic health records to identify adult patients with IIH through the ICD-10-CM classification G93.2. Eligibility requirements included: age 18 years or older at initial diagnosis, verification of IIH diagnosis through documented clinical evaluations, participation in conventional therapeutic protocols, and complete baseline clinical documentation including body mass index (BMI) measurements.

The tirzepatide intervention group was established through pharmaceutical dispensing records (identified via specific RxNorm unique identifiers) indicating tirzepatide administration alongside standard care protocols. The comparison group consisted of patients managed with

conventional therapeutics, including but not limited to acetazolamide, topiramate, and weight management strategies, without exposure to any GLP-1/GIP receptor agonists.

Exclusion parameters were comprehensively defined to encompass: secondary intracranial hypertension etiologies (validated through ICD-10 coding), including cerebral venous thrombosis and structural neurological abnormalities; prior utilization of incretin-based therapies within the preceding 12 months; pregnancy or recent post-partum status; insufficient baseline clinical data; and follow-up duration below six months. Incomplete cases were systematically removed from the analysis to ensure data quality.

2.2. Propensity Score-Matching:

To mitigate selection bias and establish comparable cohorts, we implemented a 1:1 propensity score matching protocol utilizing TriNetX's built-in analytics features. The propensity score model incorporated multiple variables including demographic characteristics such as age at diagnosis, sex, race (categorized as White, Black or African American, Asian, and Other), and ethnicity (Hispanic or Latino, Non-Hispanic or Latino). Clinical parameters included baseline BMI, comorbidity profiles including endocrine, musculoskeletal, and eye disorders, pre-existing medication usage, and healthcare utilization patterns in the year preceding cohort entry.

The matching procedure employed an optimal matching algorithm with a stringent caliper width of 0.1 standard deviations of the propensity score logit. This refined methodology transformed our initial sample of 438 tirzepatide-exposed patients and 21,654 controls into balanced cohorts of 435 and 870 patients respectively, achieving optimal covariate balance with standardized differences below 0.1 for all matched variables.

2.3. Outcome Definition and Monitoring:

Primary endpoints were monitored through structured database queries at 3-month, 6-month, 12-month, and 24-month intervals post-treatment initiation. Disease-specific markers included papilledema severity (ICD-10: H47.1), headache frequency and intensity (ICD-10: G44.-), and visual function parameters (ICD-10: H53.-, H54.-). Treatment resistance was defined through a composite of indicators including requirement for escalation of medical therapy, progression to surgical intervention, need for CSF diversion procedures, or optic nerve decompression/ONSF necessity.

Secondary endpoints focused on metabolic parameters, particularly BMI trajectories and body composition changes, documented through standardized clinical measurements at each follow-up interval. These measurements were extracted directly from structured clinical data fields, with both absolute changes and percentage reductions calculated to provide comprehensive assessment of weight-related outcomes.

2.4. Statistical Methodology:

All analyses were performed using TriNetX's analytical tools, which employ standardized statistical methodologies. For primary outcomes, we calculated risk ratio/relative risk (RR) with corresponding 95% confidence intervals, and absolute risk differences between groups. Continuous variables were expressed as means \pm standard deviations, with between-group comparisons conducted using Student's t-tests. Categorical variables were analyzed using chi-square tests or Fisher's exact tests where appropriate. For BMI analysis, we computed both absolute and baseline-adjusted differences between groups, with temporal trends assessed through longitudinal analysis features. Statistical significance was consistently defined as $p < 0.05$, with exact p-values reported where available. Multiple comparison adjustments were applied using the Benjamini-Hochberg procedure to control the false discovery rate.

3. Results:

We evaluated baseline characteristics between tirzepatide-exposed and control cohorts through propensity score-matching (**Table 1**). Our initial sample comprised 193 patients in the tirzepatide group and 20,683 in the control group, which was subsequently matched to achieve balanced cohorts of 193 patients each. The demographic composition revealed a predominantly female population in both matched groups (91.71% vs 92.75%, $p=0.7038$). Mean age was comparable between matched cohorts (37.7 ± 8.52 vs 37.5 ± 8.78 years, $p=0.8140$), though we observed a persistent significant difference in body mass index (BMI) (41.3 ± 8.82 vs 38.7 ± 9.33 kg/m², $p=0.0089$).

Our matched cohorts demonstrated significant balance across racial and ethnic distributions, with White patients constituting the majority (72.02% vs 75.65%, $p=0.4176$), followed by Black or African American (16.06% vs 14.51%, $p=0.6713$) and Hispanic or Latino patients (5.70% vs 7.25%, $p=0.5350$). Notably, we achieved a balance in comorbidity profiles post-matching, with comparable rates of endocrine (96.37% vs 96.89%, $p=0.7778$), musculoskeletal (72.02% vs 70.47%, $p=0.7358$), and eye disorders (67.36% vs 65.29%, $p=0.6666$). Additional comorbidities, including digestive system disorders (63.21% vs 64.77%, $p=0.7504$) and circulatory system disorders (26.94% vs 25.91%, $p=0.8174$), were also well-balanced between groups (**Figure 1**).

3.1. Symptoms and Outcomes Analysis:

Our analysis revealed significant therapeutic benefits of tirzepatide as an adjunctive therapy across all measured outcomes in patients with IIH (**Table 2**). The most significant improvements were observed in papilledema outcomes, with the tirzepatide group demonstrating a 67.7% reduction in risk at three months (RR 0.323, 95% CI 0.163-0.639, $p=0.001$). This promising

protective effect was maintained throughout the follow-up period, showing a 68% risk reduction at 24 months (RR 0.320, 95% CI 0.189-0.542, $p < 0.001$).

Visual outcomes showed similarly significant improvements, with tirzepatide treatment associated with a 61.5% reduction in risk of visual disturbances or blindness at three months (RR 0.385, 95% CI 0.191-0.776, $p = 0.005$). The protective effect strengthened over time, reaching a 73.9% risk reduction at 24 months (RR 0.261, 95% CI 0.143-0.477, $p < 0.001$), representing the most progressive improvement among all measured outcomes.

Headache symptoms showed also statistically significant improvement with tirzepatide therapy. The intervention group demonstrated a 23.3% reduction in headache risk at three months (RR 0.767, 95% CI 0.597-0.987, $p = 0.037$), with sustained benefit showing a 19.7% risk reduction at 24 months (RR 0.803, 95% CI 0.668-0.966, $p = 0.019$).

In cases of refractory IHH, traditionally challenging to manage, the tirzepatide group showed a 23.2% reduction in risk at three months (RR 0.768, 95% CI 0.592-0.997, $p = 0.046$), maintaining a 20.5% risk reduction at 24 months (RR 0.795, 95% CI 0.654-0.965, $p = 0.019$).

The risk difference analysis revealed distinctive longitudinal patterns in treatment response across all outcomes over the different follow-up timepoints in our study (**Figure 2**). The most pronounced therapeutic divergence between tirzepatide and control groups occurred at six months for most outcomes, with sustained benefits through 24 months. This pattern was particularly evident in visual disturbances and papilledema, where risk differences remained consistently significant ($p < 0.001$) throughout the follow-up period. The absolute risk reduction demonstrated clinical significance even at 24 months, with the tirzepatide group maintaining consistently lower risk profiles across all outcomes, as illustrated by the negative risk differences favoring tirzepatide treatment (**Figure 2**).

3.2. BMI Longitudinal Analysis:

The longitudinal analysis of BMI trends revealed significant differences between the tirzepatide and control groups over the 24-month follow-up period (**Table 3**). At the baseline-adjusted analysis, we observed a progressive BMI reduction in the tirzepatide group, starting with a modest decrease at three months (-0.294 kg/m^2 , 95% CI $[-0.581, -0.007]$, $p = 0.045$). This reduction became more pronounced at subsequent timepoints, reaching -0.733 kg/m^2 at six months (95% CI $[-1.012, -0.454]$, $p < 0.001$), -0.986 kg/m^2 at 12 months (95% CI $[-1.259, -0.713]$, $p < 0.001$), and achieving maximal effect at 24 months with -1.147 kg/m^2 (95% CI $[-1.415, -0.879]$, $p < 0.001$).

Follow-up participation varied between groups, with the tirzepatide group showing consistent engagement from 95 individuals at three months to 125 at 24 months, while the control group maintained slightly higher numbers, ranging from 110 to 138 participants. Despite these variations, the absolute BMI differences between groups remained statistically significant throughout the study period, with the tirzepatide group maintaining higher absolute BMI values

but showing greater relative reductions over time. This sustained difference, coupled with the progressive baseline-adjusted reductions, suggests a significant effect of tirzepatide on weight management in our IHH cohort compared to standard management alone.

4. Discussion:

The emergence of GLP-1 receptor agonists has revolutionized the therapeutic landscape for IHH, offering a novel approach that addresses both the metabolic and neurological aspects of the disease [1, 2]. While the efficacy of single-receptor GLP-1 RAs as exenatide has been demonstrated through two clinical studies on IHH patients [8, 10], our study presents the first large-scale investigation of tirzepatide, a dual GIP/GLP-1 receptor agonist [11], as an adjunctive therapy in IHH management. The complex interplay between obesity, metabolic dysfunction, and ICP regulation in IHH suggests that a dual-receptor approach may offer advantages over traditional single-receptor therapies [4, 7].

Our study represents a significant milestone advancement in IHH literature through its utilization of the TriNetX database, enabling a structured propensity score-matched analysis of 435 tirzepatide-exposed patients against 870 controls. This methodological approach addresses several limitations common to previous IHH studies, where sample sizes have typically been restricted. The careful matching process created well-balanced cohorts across demographic and clinical parameters, effectively mitigating selection bias and strengthening the validity of our findings. The rationale for investigating tirzepatide specifically stems from emerging evidence regarding the role of metabolic dysfunction in IHH pathophysiology [4, 12]. Recent research has demonstrated that adipose tissue dysfunction, particularly in the context of obesity, contributes to IHH through multiple mechanisms, including the production of pro-inflammatory adipokines and alterations in hormonal signaling [3, 12].

Our findings demonstrate significant therapeutic benefits across multiple clinical endpoints, with particularly notable improvements in papilledema and visual outcomes. The 67.7% reduction in papilledema risk at three months represents a substantial improvement over outcomes reported in previous GLP-1 RA studies [2, 8, 13]. The sustained improvement in visual outcomes, reaching a 73.9% risk reduction at 24 months, carries significant clinical implications given the potentially devastating consequences of visual deterioration in IHH. The reduction in headache symptoms, while significant, aligns with findings from previous GLP-1 RA studies, suggesting this benefit may be a class effect rather than specific to dual receptor activation [5, 8].

The superior efficacy of tirzepatide observed in our study likely reflects its unique mechanism of action through dual receptor activation. Recent evidence has elucidated the complex role of metabolic dysfunction in IHH, particularly through the action of adipose tissue as an endocrine organ [4, 14-20]. Tirzepatide's concurrent activation of GIP and GLP-1 receptors may provide more comprehensive regulation of metabolic pathways compared to single-receptor agonists. The

mechanisms likely involve modulation of Na⁺/K⁺ ATPase activity in the choroid plexus, improvement in hypothalamic function, and reduction in inflammatory mediators [2, 3, 21, 22]. Furthermore, the observed BMI reductions in our study (-1.147 kg/m² at 24 months) suggest that tirzepatide's weight loss effects contribute to therapeutic benefits through reduced intracranial venous pressure and decreased pro-inflammatory adipokine production [4, 7].

The implementation of tirzepatide in clinical practice requires careful consideration of patient selection and monitoring protocols. Based on our findings and current understanding of IIH pathophysiology, optimal candidates include patients with inadequate response to first-line treatments and those with significant metabolic dysfunction [4, 5, 14, 18]. Regular monitoring should include comprehensive ophthalmological examination, metabolic parameter assessment, and documentation of headache frequency and severity. The integration of tirzepatide into existing treatment algorithms should consider its role as an adjunctive therapy, with particular attention to dose escalation and potential interactions with standard medications such as acetazolamide [2, 8, 13, 23, 24].

Several limitations of our study warrant consideration. The TriNetX database structure precluded detailed analysis of tirzepatide dosing effects and comprehensive medication adherence data. The retrospective design introduces potential for unmeasured confounders, and the lack of standardized ICP measurements across centers may impact the generalizability of our findings. Additionally, variable follow-up periods and incomplete data on concurrent medications represent important considerations in interpreting our results.

Looking forward, our findings establish several critical priorities for future research. Prospective randomized controlled trials comparing tirzepatide with other GLP-1 RAs are essential to confirm our observed benefits [25, 26]. Additionally, investigation of tirzepatide's direct effects on CSF dynamics and inflammatory markers would enhance our understanding of its therapeutic mechanism. The development of optimized treatment protocols and investigation of combination therapy approaches represent important next steps in maximizing the potential of this promising therapeutic option [25, 26].

5. Conclusions:

Our findings establish tirzepatide as a promising therapeutic advancement in IIH management, with significant implications for clinical practice and future research directions. The dual GIP/GLP-1 receptor agonism mechanism appears to offer distinct advantages over traditional single-receptor approaches, particularly in addressing the complex interplay between metabolic dysfunction and intracranial pressure regulation. The marked improvements in papilledema and visual outcomes suggest that early intervention with tirzepatide could potentially alter the natural history of IIH, especially in cases refractory to conventional therapies. These results challenge the current paradigm of IIH treatment, suggesting that targeted metabolic interventions may be as

crucial as direct ICP-lowering strategies. The sustained therapeutic benefits observed over 24 months indicate potential disease-modifying effects that extend beyond symptomatic relief. However, the variable patient responses and complex interaction with concurrent medications underscore the need for personalized treatment approaches and careful patient selection. Critical questions remain regarding the optimal timing of tirzepatide initiation, dose optimization strategies, and potential synergistic effects with standard therapies. Future evidence should prioritize prospective randomized trials investigating these aspects, alongside mechanistic studies examining tirzepatide's direct effects on CSF dynamics and neuroinflammatory pathways. The development of biomarkers predicting treatment response and standardized protocols for monitoring therapeutic efficacy would significantly enhance clinical decision-making. As the therapeutic landscape for IIH continues to evolve, our findings suggest that incorporating metabolic modulators like tirzepatide into treatment algorithms could fundamentally transform disease management strategies. This paradigm shift necessitates a reconsideration of current treatment hierarchies and highlights the importance of addressing both the neurological and metabolic aspects of IIH for optimal patient outcomes.

Declarations:

Conflicts of Interest: N/A.

IRB Approval: Waived.

Funding Source: The project described was supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through CTSA award number: UM1TR004400. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Ethical Approvals: Waived.

Consent for Participation: N/A.

Acknowledgements: Open access funding is provided by the Qatar National Library.

Data Availability Statement: All used data is available within TriNetX database platform.

References:

1. Sheth, S., et al., *The protective role of GLP-1 in neuro-ophthalmology*. 2023. **1**(4): p. 221-238.
2. Mitchell, J.L., et al., *The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial*. 2023. **146**(5): p. 1821-1830.
3. Zhou, C., et al., *Progress and recognition of idiopathic intracranial hypertension: A narrative review*. 2024. **30**(8): p. e14895.
4. Hornby, C., et al., *Metabolic Concepts in Idiopathic Intracranial Hypertension and Their Potential for Therapeutic Intervention*. *J Neuroophthalmol*, 2018. **38**(4): p. 522-530.
5. Halloum, W., et al., *Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review*. 2024. **25**(1): p. 112.
6. Azzam, A.Y., et al., *Venous sinus stenting for idiopathic intracranial hypertension: An updated Meta-analysis*. *J Neurol Sci*, 2024. **459**: p. 122948.
7. Mollan, S.P., A.A. Tahrani, and A.J.J.N.C.P. Sinclair, *The potentially modifiable risk factor in idiopathic intracranial hypertension: body weight*. 2021. **11**(4): p. e504-e507.
8. Krajnc, N., et al., *Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension*. *J Headache Pain*, 2023. **24**(1): p. 89.
9. Palchuk, M.B., et al., *A global federated real-world data and analytics platform for research*. *JAMIA Open*, 2023. **6**(2): p. ooad035.
10. Mitchell, J.L., et al., *The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial*. *Brain*, 2023. **146**(5): p. 1821-1830.
11. Dubin, R.L., et al., *Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps*. *Diabetes Obes Metab*, 2024. **26**(12): p. 5503-5518.
12. Samancı, B., et al., *Evidence for potential involvement of pro-inflammatory adipokines in the pathogenesis of idiopathic intracranial hypertension*. 2017. **37**(6): p. 525-531.
13. Khatkar, P., et al., *Experimental drugs for the treatment of idiopathic intracranial hypertension (IIH): shedding light on phase I and II trials*. *Expert Opin Investig Drugs*, 2023. **32**(12): p. 1123-1131.
14. Westgate, C.S., et al., *Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension*. *JCI Insight*, 2021. **6**(10).
15. Korsbæk, J.J., et al., *Metabolic Dysfunction in New-Onset Idiopathic Intracranial Hypertension: Identification of Novel Biomarkers*. 2024. **96**(3): p. 595-607.
16. Colman, B.D., et al., *Understanding the pathophysiology of idiopathic intracranial hypertension (IIH): a review of recent developments*. 2024. **95**(4): p. 375-383.
17. Westgate, C.S., et al., *Increased systemic and adipose 11 β -HSD1 activity in idiopathic intracranial hypertension*. 2022. **187**(2): p. 323-333.
18. Potter, O., V. Menon, and S.P.J.E.R.o.N. Mollan, *Risk factors and disease associations in people living with idiopathic intracranial hypertension*. 2024: p. 1-9.
19. Azzam, A.Y., et al., *Safety and Efficacy of Metformin for Idiopathic Intracranial Hypertension. A US-Based Real-World Data Retrospective Multicenter Cohort Study*. 2024: p. 2024.09. 01.24312907.

20. Azzam, A.Y., et al., *Idiopathic Intracranial Hypertension and Cardiovascular Diseases Risk in the United Kingdom Women: An Obesity-Adjusted Risk Analysis Using Indirect Standardization*. 2024: p. 2024.10.20.24315837.
21. Fareed, A., et al., *Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide*. *Endocr Pract*, 2024.
22. Kassubek, R., et al., *Morphological alterations of the hypothalamus in idiopathic intracranial hypertension*. *Ther Adv Chronic Dis*, 2022. **13**: p. 20406223221141354.
23. Louis, D.N., et al., *The 2021 WHO Classification of Tumors of the Central Nervous System: a summary*. *Neuro Oncol*, 2021. **23**(8): p. 1231-1251.
24. Fargen, K.M., et al., *"Idiopathic" intracranial hypertension: An update from neurointerventional research for clinicians*. *Cephalalgia*, 2023. **43**(4): p. 3331024231161323.
25. Biousse, V. and N.J. Newman, *Clinical trials for idiopathic intracranial hypertension: what are we treating?* *Nat Rev Neurol*, 2024. **20**(1): p. 3-4.
26. Markey, K.A., et al., *Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions*. *Lancet Neurol*, 2016. **15**(1): p. 78-91.

Figure Legends:

Figure 1: Patients Enrollment Flow Diagram.





Figure 2: Risk Difference Longitudinal Analysis Over Timepoints For Outcomes.



Note: Error bars represent 95% confidence intervals. *p0.05, **p0.01, ***p0.001. Negative values favor Tirzepatide (N=193 per group).

Tables Legend:

Table 1: Baseline Characteristics of Tirzepatide Group and Control Group Before and After Propensity Score Matching for Cohorts.

Variable	Tirzepatide Before Matching	Control Before Matching	P-value Before	Tirzepatide After Matching	Control After Matching	P-value After
Sample size, n	193	20,683	N/A	193	193	N/A
Age (years), mean \pm SD	37.7 \pm 8.52	35.7 \pm 10	0.0046	37.7 \pm 8.52	37.5 \pm 8.78	0.8140
BMI, mean \pm SD	41.3 \pm 8.82	35.5 \pm 9.02	< 0.0001	41.3 \pm 8.82	38.7 \pm 9.33	0.0089
Female, n (%)	177 (91.71%)	17,633 (85.76%)	0.0183	177 (91.71%)	179 (92.75%)	0.7038
Male, n (%)	10 (5.18%)	2,504 (12.18%)	0.0030	10 (5.18%)	10 (5.18%)	1.0000
<i>Race/Ethnicity:</i>						
White, n (%)	139 (72.02%)	12,235 (59.50%)	0.0004	139 (72.02%)	146 (75.65%)	0.4176
Black or African American, n (%)	31 (16.06%)	3,913 (19.03%)	0.2955	31 (16.06%)	28 (14.51%)	0.6713
Hispanic or Latino, n (%)	11 (5.70%)	1,924 (9.36%)	0.0820	11 (5.70%)	14 (7.25%)	0.5350
Asian, n (%)	0 (0%)	299 (1.45%)	0.0915	0 (0%)	0 (0%)	-
<i>Comorbidities:</i>						
Endocrine disorders, n (%)	186 (96.37%)	8,554 (41.60%)	< 0.0001	186 (96.37%)	187 (96.89%)	0.7778
Musculoskeletal disorders, n (%)	139 (72.02%)	6,653 (32.36%)	< 0.0001	139 (72.02%)	136 (70.47%)	0.7358
Eye disorders, n (%)	130 (67.36%)	11,466 (55.76%)	0.0012	130 (67.36%)	126 (65.29%)	0.6666
Digestive system disorders, n (%)	122 (63.21%)	4,897 (23.82%)	< 0.0001	122 (63.21%)	125 (64.77%)	0.7504
Circulatory system disorders, n (%)	52 (26.94%)	3,470 (16.88%)	0.0002	52 (26.94%)	50 (25.91%)	0.8174

Table 2: Outcomes Risk For Tirzepatide Group Compared to Control Group.

Outcome	Follow-up Timepoint	Risk Ratio	95% Confidence Interval	P-value
Papilledema	3-months	0.323	(0.163, 0.639)	0.001
	6-months	0.342	(0.188, 0.622)	0.000
	12-months	0.348	(0.204, 0.593)	0.000
	24-months	0.320	(0.189, 0.542)	0.000
Headache	3-months	0.767	(0.597, 0.987)	0.037
	6-months	0.820	(0.663, 1.015)	0.066
	12-months	0.849	(0.697, 1.035)	0.103
	24-months	0.803	(0.668, 0.966)	0.019
Refractory IHH	3-months	0.768	(0.592, 0.997)	0.046
	6-months	0.813	(0.650, 1.015)	0.066
	12-months	0.843	(0.686, 1.036)	0.103
	24-months	0.795	(0.654, 0.965)	0.019
Visual Disturbances or Blindness	3-months	0.385	(0.191, 0.776)	0.005
	6-months	0.323	(0.163, 0.639)	0.001
	12-months	0.289	(0.153, 0.549)	0.000
	24-months	0.261	(0.143, 0.477)	0.000

Table 3: BMI Differences Over Follow-Time Point Comparison Between Tirzepatide Group vs. Control Group.

Follow-Up Point	Tirzepatide Group (Number of Individuals)	Tirzepatide Group BMI (Mean, SD)	Control Group (Number of Individuals)	Control Group BMI (Mean, SD)	Mean BMI Difference	95% Confidence Interval	P-value
3-months	95	39.182 ± 7.588	110	37.595 ± 9.150	1.587	(0.824, 2.350)	0.182
6-months	112	39.036 ± 7.968	127	37.447 ± 9.365	1.589	(0.838, 2.340)	0.162
12-months	124	38.396 ± 8.288	132	37.103 ± 9.205	1.293	(0.552, 2.034)	0.240
24-months	125	38.349 ± 8.266	138	37.301 ± 9.287	1.048	(0.317, 1.779)	0.336
Baseline-Adjusted BMI Difference (3-months)	-0.294						
95% Confidence Interval, P-value (3-months)	[-0.581, -0.007], P-value = 0.045						
Baseline-Adjusted BMI Difference (6-months)	-0.733						
95% Confidence Interval, P-value (6-months)	[-1.012, -0.454], P-value < 0.001						
Baseline-Adjusted BMI	-0.986						

Difference (12- months)	
95% Confidence Interval, P-value (12- months)	[-1.259, -0.713], P-value < 0.001
Baseline- Adjusted BMI Difference (24- months)	-1.147
95% Confidence Interval, P-value (24- months)	[-1.415, -0.879], P-value < 0.001